芩莲正积方联合化疗治疗晚期非小细胞肺癌临床研究

Qinlian Zhengji Prescription Combined with Chemotherapy in Treatment of Advanced Non-Small Cell Lung Cancer

目的:探讨芩莲正积方联合化疗治疗晚期非小细胞肺癌的临床疗效。方法:选取50例晚期非小细胞肺癌患者,随机分为观察组和对照组,对照组采用DP方案治疗,观察组在对照组的基础上给予苦参碱注射液静脉滴注,并配合芩莲正积方口服。治疗后观察两组患者临床疗效、生存质量、免疫功能改善情况和不良反应。结果:观察组肿瘤控制率为92.00%,对照组肿瘤控制率为72.00%,两组比较,差异有统计学意义(P<0.05)。观察组患者生存质量优于对照组,两组比较,差异有统计学意义(P<0.05)。治疗后观察组各免疫指标均略高于治疗前,且略高于对照组,但差异均无统计学意义(P>0.05)。观察组1年生存率为72.00%,显著高于对照组的52.00%,差异具有统计学意义(P<0.05)。治疗后两组患者均有不同程度的白细胞、血红蛋白、血小板下降,两组比较,差异无统计学意义(P>0.05);观察组消化道反应明显少于对照组(P<0.05);两组肾功能损害均较轻,差异无统计学意义(P>0.05)。结论:芩莲正积方联合化疗可提高晚期非小细胞肺癌患者的肿瘤控制率,改善患者生存质量,提高1年生存率,降低化疗不良反应。

Objective：To investigate the clinical efficacy of QinlianZhengji Prescription combined with Chemotherapy in treatment of advanced Non-Small Cell Lung Cancer. Methods：50 cases of patients were randomly divided into observation group and control group. DP regimen was used in treatment of the control group, while Matrine injection intravenous infusion and Qinlian Zhengji Prescription were applied in treatment of the observation group treated in addition to that of the control group. The curative effect, patients＇ quality of life ,improvement of immune function and the adverse reactions of the two groups after treatment were exam- ined. Results：The tumor control rate was 92.00% in the observation group and 72.00% in the control group, with the difference being statistically significant （P 〈 O. 05）. The quality of life of the observation group was better than that of control group and the difference was statistically significant （P 〈 0.05 ）. After treatment, the immune parameters of the observation group were slightly higher than that before treatment and slightly higher than that of the control group, but the difference was not statistically significant （ P 〉 0.05 ）. The one-year survival rate of the observation group was 72.00%, which was significantly higher than that （ 52. 00% ） of the control group （ P 〈 0.05）. There were no significant differences between the two groups in the decrease of white blood cell, hemoglobin and platelet count （P 〉 0.05 ）. The gastrointestinal reaction of the observation group was significantly less than that of the control group （P 〈 O. 05 ）. The renal function damage were mild, and the difference between the two groups was not significant （ P 〉 0.05 ）. Conclusion ： Qinlian Zhengji Prescription combined with Chemotherapy in treatment of advanced Non-Small Cell Lung Cancer can improve the tumor control rate, improve the quality of life of patients,improve the 1-year survival rate and reduce the adverse reactions of chemotherapy.